Catalio Capital Management LP Sells 398,909 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Catalio Capital Management LP reduced its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 61.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 252,901 shares of the company’s stock after selling 398,909 shares during the period. Structure Therapeutics comprises about 3.3% of Catalio Capital Management LP’s investment portfolio, making the stock its 10th biggest position. Catalio Capital Management LP’s holdings in Structure Therapeutics were worth $17,589,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. State of Wyoming bought a new position in Structure Therapeutics during the 2nd quarter valued at about $28,000. EverSource Wealth Advisors LLC lifted its holdings in Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares during the last quarter. CWM LLC lifted its holdings in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its holdings in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after purchasing an additional 1,146 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Structure Therapeutics during the 4th quarter valued at about $127,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GPCR has been the subject of several analyst reports. Citizens Jmp cut their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a report on Friday, February 27th. BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the company an “outperform” rating in a report on Tuesday, March 17th. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Canaccord Genuity Group initiated coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. Finally, Wolfe Research initiated coverage on shares of Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $106.75.

Structure Therapeutics Trading Up 4.9%

Shares of NASDAQ GPCR opened at $45.00 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $15.80 and a 1-year high of $94.90. The company has a market cap of $3.20 billion, a PE ratio of -51.72 and a beta of -1.35. The company has a 50-day moving average of $43.09 and a two-hundred day moving average of $57.53.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. As a group, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.